



NEWS



Australian Vaccine First In World To Show Ability To Totally Block Covid-19 Virus Transmission

Australian company, Vaxine Pty Ltd, has developed a protein based COVID-19 vaccine that completely blocks virus transmission to non-immune individuals. The COVAX-19™ vaccine being developed by Australian company, Vaxine Pty Ltd, is set to be a game-changer in the fight against the COVID-19 pandemic and could allow earlier re-opening of national borders after it was shown to not only protect but also to completely block virus transmission to non-immune animals.

Vaxine's biggest challenge now is to quickly raise the financial resources to complete Phase 3 human clinical trials and get Covid-19 vaccine manufactured at large scale which is likely to be in the order of \$50 million dollars.

In another major breakthrough, Vaxine have also successfully created a breakthrough multivalent vaccine to protect against the new Covid-19 virus variants including the worrying South African, Brazilian and Indian mutant strains. The results of this multivalent Covid-19 vaccine formulation in animal testing is looking very promising.

Vaxine's COVAX-19™ vaccine is a subunit vaccine based on synthetic protein produced using harmless insect cells to which Vaxine's proprietary Advax polysaccharide adjuvant is added as a vaccine turbocharger to maximise the vaccine's effectiveness and durability.

Vaxine is currently working with partners in overseas countries to assist in the upcoming phase 3 human clinical trials.

Vaxine has a long history of successfully developing pandemic vaccines, having previously developed vaccines against the SARS 3 and MERS coronaviruses that were shown to be highly protective in relevant animal models.

Reference:
[EIN Presswire](#)